Two new LAB150 projects identified to create novel therapeutics for Cystic Fibrosis and Respiratory Syncytial Virus


Toronto, Canada, 27 February, 2019:

MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. The projects aim to develop novel therapeutics for the treatment of cystic fibrosis and of respiratory syncytial virus, respectively. LAB150 is a partnership between Evotec AG and MaRS Innovation with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms and expertise.

For further information on the new LAB150 projects, click here for MaRS Innovation’s press release.